**Cancer Cell**

**N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells**

**Graphical Abstract**

**Highlights**
- N-Myc and AKT1 drive NEPC from human prostate epithelium
- Prostate epithelial cells can give rise to neuroendocrine and epithelial cancers
- N-Myc is essential for tumor maintenance in tumors initiated by N-Myc and AKT1
- Destabilization of N-Myc through Aurora A kinase inhibition induces tumor cell death

**Authors**
John K. Lee, John W. Phillips, Bryan A. Smith, ..., W. Clay Gustafson, Jiaoti Huang, Owen N. Witte

**Correspondence**
owenwitte@mednet.ucla.edu

**In Brief**
Lee et al. establish N-Myc as a driver of neuroendocrine prostate cancer (NEPC) and a target for intervention. N-Myc and activated AKT1 are sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and NEPC, both of which can be derived from a common epithelial precursor.

**Accession Numbers**
GSE77624
GSE77368
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells

John K. Lee,1,2 John W. Phillips,3 Bryan A. Smith,3 Jung Wook Park,3 Tanya Stoyanova,3 Erin F. McCaffrey,3 Robert Baertsch,4 Artem Sokolov,4 Justin G. Meyerowitz,5,6,7 Colleen Mathis,3 Donghui Cheng,8 Joshua M. Stuart,4 Kevan M. Shokat,5,7,12 W. Clay Gustafson,5,9 Jiaoti Huang,8,10 and Owen N. Witte3,8,11,12,*

1Division of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
2Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
3Department of Microbiology, Immunology, and Medical Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
4Center for Biomolecular Science and Engineering, Jack Baskin School of Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA
5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA
6Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA
7Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA
8Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA
9Department of Pediatrics, UCSF Benioff Children’s Hospital, University of California, San Francisco, San Francisco, CA 94158, USA
10Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
11Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA
12Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
*Correspondence: owenwitte@mednet.ucla.edu
http://dx.doi.org/10.1016/j.ccell.2016.03.001

SUMMARY

MYCN amplification and overexpression are common in neuroendocrine prostate cancer (NEPC). However, the impact of aberrant N-Myc expression in prostate tumorigenesis and the cellular origin of NEPC have not been established. We define N-Myc and activated AKT1 as oncogenic components sufficient to transform human prostate epithelial cells to prostate adenocarcinoma and NEPC with phenotypic and molecular features of aggressive, late-stage human disease. We directly show that prostate adenocarcinoma and NEPC can arise from a common epithelial clone. Further, N-Myc is required for tumor maintenance, and destabilization of N-Myc through Aurora A kinase inhibition reduces tumor burden. Our findings establish N-Myc as a driver of NEPC and a target for therapeutic intervention.

INTRODUCTION

Neuroendocrine prostate cancer (NEPC) makes up less than 2% of all primary prostate cancers (Helpap et al., 1999). However, treatment-related NEPC often emerges during androgen deprivation therapy for prostate adenocarcinoma, the predominant subtype of prostate cancer (Beltran et al., 2014). The term NEPC describes a heterogeneous group of neuroendocrine tumors defined morphologically that include well-differentiated carcinoid, adenocarcinoma with neuroendocrine differentiation, adenocarcinoma with Paneth cell-like neuroendocrine differentiation, mixed neuroendocrine carcinoma-acinar adenocarcinoma, and the more aggressive large-cell carcinoma and small-cell carcinoma (Epstein et al., 2014). NEPC is also distinguished from prostate adenocarcinoma by the expression of neuroendocrine differentiation markers and the loss of expression of the androgen receptor (AR) and prostate-specific antigen (Wang and Epstein, 2008). Patients with aggressive NEPC have limited treatment options and succumb to the disease within a year (Spiess et al., 2007).

Significance

Our studies underscore the functional significance of the MYCN oncogene in NEPC. Deregulated expression of MYCN combined with myristoylated AKT1 drives the development of prostate adenocarcinoma and NEPC from human prostate epithelial cells. We present direct evidence that both tumor subtypes can be derived from a common epithelial precursor. N-Myc expression is essential to maintain the tumor state, indicating that N-Myc may be a therapeutic target in MYCN-amplified NEPC. Pharmacologic disruption of N-Myc by the targeted inhibition of Aurora A kinase causes a marked reduction in tumor growth. In summary, we provide insight into the pathogenesis of NEPC and the rationale for a therapeutic strategy in this deadly disease.
Aggressive NEPC represents a lethal endpoint in the progression of prostate cancer from prostate adenocarcinoma to castration-resistant prostate cancer (CRPC) to NEPC. Neuroendocrine transdifferentiation is an adaptive mechanism of resistance to androgen withdrawal observed in vitro and in vivo (Lin et al., 2014; Shen et al., 1997). The phenotypic conversion to NEPC is associated with recurrent genetic lesions including mutation or deletion of RB1 and TP53 as well as the overexpression and genomic amplification of MYCN and AURKA (Beltran et al., 2011; Tan et al., 2014). NEPCs also harbor genetic abnormalities present in prostate adenocarcinomas such as ETS rearrangements and PTEN mutations (Beltran et al., 2011; Tan et al., 2014), indicating that these cancer types may arise from a common clonal origin.

Prior work has identified multipotent stem and progenitor cells within the basal epithelial compartment of the mouse and human prostate that give rise to basal, luminal, and neuroendocrine cells (Goldstein et al., 2008, 2010). Others have shown through lineage tracing studies that both basal and luminal cells in the mouse prostate can be cell types of origin of cancer (Choi et al., 2012; Wang et al., 2009). Importantly, we have demonstrated that naive basal cells in the human prostate can serve as targets of direct transformation. The overexpression of ERG and constitutively active myristoylated AKT1 (myrAKT1) initiated prostate cancer from human prostate basal cells (Goldstein et al., 2010). Loss of the tumor suppressor PTEN is found in 70% of prostate cancers and leads to the activation of AKT1, a common early event in prostate cancer tumorigenesis (Gray et al., 1998; Wu et al., 1998). Further studies showed that the deregulated expression of c-Myc and myrAKT1 in human basal cells generated prostate adenocarcinoma and squamous cell carcinoma from a common precursor (Stoyanova et al., 2013). The c-Myc/myrAKT1 human prostate cancer model highlights the potential for biphenotypic tumors to arise from divergent differentiation during tumorigenesis.

The Myc family of proto-oncogenes (MYC, MYCL, and MYCN) encodes a group of multi-functional transcription factors whose deregulation plays a role in the initiation and maintenance of most human cancers (Dang, 2012). MYC is commonly overexpressed and amplified in prostate cancer (Fleming et al., 1986; Jenkins et al., 1997). A recent study has demonstrated recurrent, focal amplification of MYCL in 27% of localized prostate cancers (Boutros et al., 2015). MYCN has been shown to be overexpressed and amplified in approximately 40% of NEPCs but only 5% of prostate adenocarcinomas (Beltran et al., 2011). Numerous studies have implicated N-Myc as a critical oncoprotein required for the development of neural and neuroendocrine tumors (Beltran, 2014). Here, we sought to evaluate the functional role of N-Myc in the initiation and maintenance of human NEPC.

RESULTS

N-Myc and myrAKT1 Overexpression in Human Prostate Basal Cells Initiates NEPC and Prostate Adenocarcinoma

To investigate whether N-Myc can initiate prostate cancer from human prostate epithelial cells, we used a tissue regeneration model of prostate cancer developed by our group (Figure 1A) (Goldstein et al., 2010; Stoyanova et al., 2013). Benign regions of prostate tissue from patients undergoing prostatectomy were dissociated to single cells. Basal epithelial cells were purified based on cell surface markers (CD45/CD49f). AKT1 was introduced as a sensitizing oncogenic event as it is frequently activated in prostate cancers including NEPCs (Figure 1D) and the overexpression of myrAKT1 initiates pre-malignant prostate intraepithelial neoplasia in our human prostate transformation assay (Stoyanova et al., 2013). Enforced expression of N-Myc and activated AKT1 in the epithelial cells was
The overexpression of N-Myc and myrAKT1 in sets of prostate basal cells from five human prostatectomy specimens (Table S1) produced tumors (Figure 1B) after 6–10 weeks with no evidence of metastatic disease. Histology of the N-Myc/myrAKT1 tumors revealed regions of high-grade adenocarcinoma and infrequent squamous cell carcinoma like the human c-Myc/myrAKT1 tumors described previously (Stoyanova et al., 2013). Some regions exhibited high nuclear-to-cytoplasmic ratio, frequent mitotic figures, and apoptotic features consistent with NEPC, including areas of small-cell prostate carcinoma (SCPC) (Figures 1C and S1A) (Wang and Epstein, 2008). Other regions of the tumors were consistent with mixed neuroendocrine carcinoma-acinar adenocarcinoma (Figure 2B). The tumors expressed N-Myc and activated AKT1 (Figure 1D), and their human origin was confirmed by immunostaining for human leukocyte antigen (HLA) class I ABC (Figure S1C). N-Myc/myrAKT1 tumors also expressed the luminal marker cytokeratin 8 (CK8) but lacked the basal marker p63 (Figure 1E), indicating loss of the basal cell layer that is a hallmark of prostate cancer.

To evaluate whether luminal prostate epithelial cells could also be transformed by N-Myc and myrAKT1, we isolated luminal cells from four benign human prostates based on cell surface markers (CD45 Trop2+CD49flow) and transduced them in a comparable manner. Similar to prior studies (Goldstein et al., 2010; Stoyanova et al., 2013), human luminal cells did not produce tumors after oncogenic challenge (data not shown).

While the diagnosis of NEPC is usually made by the recognition of classic histologic features, assessment of neuroendocrine marker expression by immunohistochemistry (IHC) is often performed to confirm the clinical diagnosis (Epstein et al., 2014). The neuroendocrine carcinoma in the N-Myc/myrAKT1 tumors demonstrated expression of neural cell adhesion molecule 1 (NCAM1), chromogranin A (CHGA), synaptophysin (SYP), thyroid transcription factor-1 (TTF-1), and forkhead box A2 (FOXA2) (Mirosevich et al., 2006; Yao et al., 2006). We detected immunostaining of these proteins in the regions of neuroendocrine carcinoma but not of adenocarcinoma in the N-Myc/myrAKT1 tumors (Figures 2A–2C). While all tumors showed morphologic evidence of NEPC, the expression pattern of the neuroendocrine markers was heterogeneous with only one tumor expressing all five markers (Figure 2D). This heterogeneity in expression of markers is similar to what is appreciated in human NEPC specimens (Yao et al., 2006).

N-Myc/myrAKT1 Tumors Are Castration Resistant

An invariant feature of late-stage human prostate cancer including NEPC is castration-resistant proliferation. The N-Myc/myrAKT1 tumors exhibited absent AR expression by IHC (Figure 2A), by immunoblotting (Figure 2E), and by gene expression (Figure 4D). We assessed the functional dependence of N-Myc/myrAKT1 tumor growth on androgens by subcutaneously injecting the CD49flow tumor cells in intact or castrate animals. Passage of CD49flow cells (Stoyanova et al., 2013) from N-Myc/myrAKT1 tumors gave rise to tumors demonstrating mixed neuroendocrine carcinoma and adenocarcinoma (Figure S1B). No difference in the growth kinetics of the tumors was observed in intact and castrate hosts (Figure 3A), indicating that the N-Myc/myrAKT1 tumors are castration resistant. In contrast, the androgen-dependent human prostate cancer cell line LNCaP formed tumors.
in intact animals but showed no growth in castrate animals (Figure 3A).

The histology of the N-Myc/myrAKT1 tumors passaged in castrate mice also showed mixed neuroendocrine carcinoma and adenocarcinoma on a background of necrosis (Figure S1B). To quantify the relative percentage of each cancer subtype by area in the tumors, we implemented smart image segmentation to differentiate neuroendocrine carcinoma and adenocarcinoma on H&E-stained sections (Figures S2A–S2C). We noted a progressive enrichment of the neuroendocrine carcinoma within the tumor with successive passage in castrate mice, from 9% in the primary tumor to 28% in the tertiary tumor (Figure 3B). These results suggest a statistically significant but subtle competitive advantage of NEPC upon serial propagation in castrate conditions.

**N-Myc/myrAKT1 Tumors Are Invasive and Metastatic**

To gauge the metastatic potential of the N-Myc/myrAKT1 tumors, we first used a tail vein assay to model the invasion-metastasis cascade (Valastyan and Weinberg, 2011). As a source of tumor cells, we dissociated an N-Myc/myrAKT1 tumor to single cells and propagated them in HITES media (Carney et al., 1981). N-Myc/myrAKT1 tumor cells and the non-metastatic human prostate cancer cell line LNCaP were transduced with a lentivirus expressing firefly luciferase (Luc) to produce the N-Myc/myrAKT1-Luc and LNCaP-Luc sublines. Tumor cells were injected into the tail veins of NSG mice. Bioluminescence was detected in the hindlimbs and pelvis in two of three N-Myc/myrAKT1-Luc mice on day 21, whereas signal was absent in LNCaP-Luc mice (Figure 3C). Necropsy of the mice showed tumors involving limb bones, sacrum, and liver (Figure 3D). We did not appreciate macrometastatic disease in the lungs despite bioluminescent imaging showing localization of N-Myc/myrAKT1-Luc cells to the lungs immediately after tail vein injection (Figure S2D). However, microscopic review of lung sections revealed numerous foci of micrometastatic disease (Figure S2E).

To confirm these findings, we performed an orthotopic injection assay of metastasis, which necessitates local invasion and intravasation, in addition to metastatic processes required for the tail vein assay. N-Myc/myrAKT1-Luc or LNCaP-Luc tumor cells were implanted into the left lateral lobes of the prostates of NSG mice. Mice were sacrificed on day 74 because of
abdominal distention of the N-Myc/myrAKT1-Luc mice. Imaging prior to euthanasia revealed multiple areas of bioluminescence in three of three N-Myc/myrAKT1-Luc mice while signal was confined to the prostate in LNCaP-Luc mice (Figure 3E). Necropsy of the N-Myc/myrAKT1-Luc mice showed extensive disease in lymph nodes and vital organs including liver and kidney (Figure 3F).

The tumors from the metastasis models exhibited a mixed phenotype of neuroendocrine carcinoma and adenocarcinoma identical to the parental tumor (Figures 3G and 3H). They also retained expression of the linked fluorescent markers from the N-Myc and myrAKT1 proviruses, HLA Class I ABC, and the neuroendocrine marker FOXA2 (Figures S2F–S2G). Collectively, these findings indicate that N-Myc/myrAKT1 tumor cells are highly aggressive and proficient in the multi-step process of metastatic dissemination.

**Molecular Characterization of N-Myc/myrAKT1 Tumors**

We then questioned whether the N-Myc/myrAKT1 tumors demonstrated molecular properties of human NEPC. Previously, Beltran et al. (2011) analyzed seven NEPCs (five SCPCs) and 30 prostate adenocarcinomas by next-generation RNA sequencing (RNA-seq) to illustrate gene networks involving AR signaling, neuroendocrine processes, and cell-cycle regulation that distinguish these entities. To evaluate global transcriptome features in the N-Myc/myrAKT1 tumors, we harvested three N-Myc/myrAKT1 tumors, isolated regions of neuroendocrine carcinoma and adenocarcinoma from frozen sections by laser capture microdissection, and processed the specimens for RNA-seq analysis (Figure 4A).

Within each of the tumors, we identified fewer than 1,500 genes differentially expressed (>4-fold) between the neuroendocrine carcinoma and adenocarcinoma. Gene set enrichment analysis of differentially expressed genes (>4-fold) in the N-Myc/myrAKT1 tumor derived from patient 1 showed enrichment for neuronal pathways including targets of NRSF/REST, a master repressor of neural genes (Chong et al., 1995), in the neuroendocrine carcinoma (Figure 4B). The adenocarcinoma was enriched in stem cell-associated pathways involving BMI1, SHH, NANOG, and WNT. On the other hand, the neuroendocrine carcinoma and adenocarcinoma components of the N-Myc/myrAKT1 tumors generated from patients 2 and 4 showed differential expression (>4-fold) of only 114 and 80 genes.

We generated a weighted 50-gene predictor to identify the gene expression features that most discriminate NEPCs from prostate adenocarcinomas in the Beltran et al. (2011) dataset (Table S2). Gene ontology of this NEPC gene signature identified biological processes such as secretion, neurotransmitter transport, neuron differentiation, and glial and oligodendrocyte fate. The predictor was applied to the N-Myc/myrAKT1 tumors to derive gene signature scores that approximate their likeness to NEPC. Both the neuroendocrine carcinoma and adenocarcinoma components of the N-Myc/myrAKT1 tumors scored positively but intermediate in value to the Beltran et al. (2011) tumors (Figure 4C).

Like the NEPCs profiled by Beltran et al. (2011), both components of the N-Myc/myrAKT1 tumors showed low levels of expression of the epithelial marker TACSTD2, AR, and the androgen-regulated genes NKX3-1, KLK3, and TMPRSS2 (Figure 4D). Consistent with our IHC results, expression of the neuroendocrine markers CHGA, SYP, NCAM1, and ENO2 was heterogeneous (Figures 2D and 4D). MYCN was highly expressed from the integrated proviruses in the N-Myc/myrAKT1 tumors. We also identified elevated levels of the cell-cycle regulation gene AURKA (Beltran et al., 2011; Mosquera et al., 2013). Our gene expression analysis also demonstrated that the polycomb genes CBX2 and EZH2 and other recently identified NEPC epigenetic regulators (Clermont et al., 2015) are upregulated in the N-Myc/myrAKT1 tumors and the Beltran et al. (2011) NEPCs (Figure 4D). These results show that the N-Myc/myrAKT1 tumors exhibit many of the defining molecular attributes that exemplify human NEPC.

To determine whether significant genomic abnormalities occur during progression to NEPC in our model, we performed high-resolution copy number analysis on three N-Myc/myrAKT1 tumors by array comparative genomic hybridization (aCGH). Two tumors exhibited no large chromosomal anomalies while one tumor showed a gain in chromosome 7 (Figure S3 and Table S3). Copy number alterations were identified in more than one tumor but these mapped to genomic regions of copy number polymorphism based on the dbVar and DGVa databases (Table S3). These findings suggest that N-Myc and myrAKT1 drive the transformation of human prostate epithelial cells to NEPC without the need for large-scale genetic abnormalities.

We also performed whole-exome sequencing of the tumors with an average of ~70-fold coverage to evaluate for mutations acquired during tumorigenesis. We calculated a mutation rate of 3.5 per megabase which is higher than the 2.0 per megabase described in heavily treated CRPC (Grasso et al., 2012). This value may be inflated due to the lack of matched benign samples in our analysis and the dependence on SNP filters. Unique mutations were identified in CCDC168, GLYAT, OR2W3, SMARCA2, and ZFPM1 in more than one tumor (Table S4). Loss of SMARCA2, a catalytic subunit of the SWI/SNF chromatin remodeling complex, promotes androgen-independent proliferation in mouse prostate epithelial cells via E2F1 (E2F transcription factor 1) deregulation (Shen et al., 2008). Our analysis did not reveal mutations in genes altered at high frequency in advanced prostate cancer such as AR, TP53, RB1, and FOXA1 (Grasso et al., 2012).

**Human N-Myc/myrAKT1 Prostate Cancer Cells Are Highly Tumorigenic and Demonstrate Plasticity**

The propagation of N-Myc/myrAKT1 tumor cells in vitro led to the establishment of a cell line named LASCPC-01. These cells grow rapidly in suspension (doubling time ~18 hr) as floating and attached clusters reminiscent of small-cell lung cancer cell lines (Figure 5A) (Carney et al., 1981). Immunoblot analysis of LASCPC-01 cells showed expression of N-Myc and activated AKT1, AURKA, and the neuroendocrine markers ASCL1 and NSE (Figure 5B). ASCL1 is a pro-neural transcription factor expressed in NEPC (Rapa et al., 2008). Conventional karyotyping of LASCPC-01 cells showed a 46 X,Y male karyotype without chromosomal abnormalities (Figure 5C). Copy number analysis of the LASCPC-01 cell line revealed a mosaic gain of 1q23.1-1q44 (Figure S3 and Table S3).

To evaluate the capacity of N-Myc/myrAKT1 prostate cancer cells to propagate tumors, we performed a limiting dilution
Figure 4. Transcriptome Profiling of the N-Myc/myrAKT1 Tumors Demonstrates Similarity to Human NEPC

(A) Schematic of the laser capture microdissection of matched regions of adenocarcinoma and neuroendocrine carcinoma in an N-Myc/myrAKT1 tumor and the workflow for whole-transcriptome shotgun sequencing.

(B) Gene set enrichment analysis for genes differentially expressed (>4-fold) in the adenocarcinoma or neuroendocrine carcinoma from the N-Myc/myrAKT1 tumor derived from patient 1.

(C) Neuroendocrine prostate cancer signature scores ± SD for Beltran et al. (2011) neuroendocrine prostate cancer (NEPC, n = 7), N-Myc/myrAKT1 adenocarcinoma (NA ADCA, n = 3), N-Myc/myrAKT1 neuroendocrine carcinoma (NA NECA, n = 3), and Beltran et al. (2011) adenocarcinoma (ADCA, n = 30).

(D) Heatmap of a selection of genes in NA ADCA, NA NECA, Beltran et al. (2011) NEPC, and Beltran et al. (2011) ADCA samples (contrast = ±2^2).

See also Figure S3 and Tables S2, S3, and S4.
We estimated that 1 in 6.5 cells (95% confidence interval [CI], 2.8–14.9) exhibited tumor regenerative capacity (Hu and Smyth, 2009). In all tumors, including those from singly xenografted N-Myc/myrAKT1 tumor cells, we discovered mixed neuroendocrine carcinoma and adenocarcinoma similar to the parental N-Myc/myrAKT1 tumor (Figures 5E, S1A, and S4A). This finding suggested that a single N-Myc/myrAKT1 tumor clone could give rise to neuroendocrine carcinoma and adenocarcinoma.

To confirm this observation, we performed single-cell sorting to expand individual N-Myc/myrAKT1 tumor cell clones from the LASCPC-01 cell line (Figure 5F). Eleven clonal sublines of LASCPC-01 were subcutaneously xenografted in NSG mice and generated tumors in 4 weeks (Figure 5F). Histologic examination showed that all clonal subline xenograft tumors exhibited both neuroendocrine carcinoma and adenocarcinoma phenotypes (Figures 5G and S4B). These results indicate that N-Myc and myrAKT1 cooperate to produce cancer cells marked by high tumor-propagating potential and the capacity to generate biphenotypic prostate tumors.

N-Myc Expression Is Essential for Tumor Maintenance in N-Myc/myrAKT1 Tumors

We next questioned whether N-Myc expression is required for tumor maintenance. Studies in MYC-driven mouse models of osteogenic sarcoma, lymphoma, and hepatocellular carcinoma have shown that inactivation of c-Myc reverses tumorigenesis through the induction of proliferative arrest, differentiation, cellular senescence, and apoptosis (Jain et al., 2002; Wu et al., 2007). To address the question of N-Myc dependence, we used a lentivirus with doxycycline-inducible N-Myc expression and a lentivirus with constitutive myrAKT1 expression (Figure 6A) in our tissue regeneration model of prostate cancer (Figure 1A). Eight weeks after implantation of the graft in an NSG mouse supplemented with a doxycycline diet, we harvested an inducible N-Myc/myrAKT1 tumor with the same histologic features of mixed NEPC as the constitutive N-Myc/myrAKT1 tumors (Figures 6B and S1A).

While dissociated cells from the inducible N-Myc/myrAKT1 tumor propagated tumors in mice fed doxycycline, they did not form tumors in mice that were not fed doxycycline (Figure 6C). In mice that were initially supplemented with doxycycline and allowed to establish inducible N-Myc/myrAKT1 tumors, doxycycline withdrawal led to a rapid and significant regression of the tumors within 96 hr (Figure 6C). Immunoblot analysis of these tumors after doxycycline withdrawal revealed a dramatic decrease in N-Myc protein levels (Figure 6D). Further, histologic evaluation of the tumors 72 hr after doxycycline withdrawal showed significant necrosis with a remarkable decline in cellularity (Figure 6E).
These results demonstrate that N-Myc is necessary for tumor maintenance in our human transformation model of NEPC and suggest that N-Myc is an important therapeutic target in MYCN-amplified NEPC.

**Pharmacologic Inhibition of N-Myc Dependence in NEPC**

AURKA expression in the N-Myc/myrAKT1 tumors (Figure 4D) and LASCPC-01 cell line (Figure 5B) is consistent with the concept of a feedforward loop between N-Myc and AURKA identified in childhood neuroblastoma (Otto et al., 2009). N-Myc induces the expression of AURKA, and AURKA regulates the stability of N-Myc through a kinase-independent protein interaction with N-Myc and the Fbxw7 ubiquitin ligase that prevents N-Myc proteolysis. Treatment of MYCN-amplified neuroblastoma cell lines with the Aurora A kinase inhibitor MLN8237 reduced N-Myc protein levels by up to 60% and suppressed growth (Brockmann et al., 2013). MLN8237 is now being evaluated in a clinical trial for NEPC (Beltran et al., 2011). Recently, a class of conformation-disrupting (CD) AURKA inhibitors was designed and optimized to potently destabilize N-Myc (Gustafson et al., 2014). The lead compound, CD532, directly interacts with AURKA and induces a global conformational shift, disrupting the AURKA/myc-N-Myc protein complex and promoting the degradation of N-Myc by the ubiquitin-proteasome pathway. Further, the cytotoxic activity of CD532 was evaluated in human cancer cell lines, and sensitivity to CD532 strongly correlated with amplification and expression of MYCN. Human prostate cancer cell lines were not tested.

We therefore sought to test CD532 in our N-Myc/myrAKT1 prostate cancer model to evaluate its therapeutic potential in NEPC. After 3 hr of treatment with CD532, LASCPC-01 cells showed a dose-dependent decline in N-Myc protein levels, inhibition of Aurora A kinase activity (phosphorylation of histone H3), and induction of cleaved PARP (Figure 7A). Diminished N-Myc protein expression was identified in LASCPC-01 cells treated with CD532 at doses of 250 nM and greater. On the other hand, treatment with the pan-Aurora kinase inhibitor VX-680 and MLN8237 did not reduce N-Myc protein levels over the same time frame (Figure 7B) and across a range of doses and time points (Figure SSA), showing differences in the ability of these AURKA inhibitors to destabilize N-Myc and inhibit Aurora A kinase activity. CD532 induced a log reduction in LASCPC-01 cell viability at 3 hr (Figure 7C) coincident with a rapid decline in N-Myc protein levels and accompanied by increased cleaved caspase-3 (Figure 7D). Cell-cycle analysis also confirmed a significantly increased sub-G1 population consistent with cell death (Figure 7E). Treatment with MLN8237 or cabazitaxel, a taxane approved for the treatment of metastatic CRPC, showed minimal early effects relative to DMSO treatment (Figures 7C and 7E). The half-maximal effective concentration (EC50) of CD532 in LASCPC-01 cells was 99.4 nM (95% CI, 81.7–120.8 nM) at 48 hr (Figure 7F). In contrast, the EC50 values of the LNCaP and DU145 human prostate cancer cell lines were approximately 20-fold higher (Figure SSA). These findings suggest that the inhibitory effect of CD532 is more specific for N-Myc-driven prostate cancer. To show that the ubiquitin-proteasome pathway is critical for N-Myc destabilization by CD532, LASCPC-01 cells were treated with a dose range of CD532 and the proteasomal inhibitor MG-132. MG-132 stabilized N-Myc but did not affect the inhibition of Aurora A kinase activity (Figure S5C).
We also assessed the human kinome interaction profile of CD532 using an active site-directed competition binding assay to characterize off-target interactions (Karaman et al., 2008). Aside from AURKA, CD532 kinase interactors include cyclin-dependent kinases like CDK2 and CDK7, KIT, FLT3, PDGFRB, RET, and FGF receptors (Figure S5D and Table S5). Inhibition of these targets may potentiate the N-Myc destabilizing effects of CD532. Relative to clinical kinase inhibitors, CD532 exhibited a favorable kinase selectivity profile comparable with crizotinib of CD532. Relative to clinical kinase inhibitors, CD532 exhibited of CD532, the tumors were harvested and assayed for N-Myc, cleaved caspase-3, and GAPDH as a loading control.

To examine the in vivo effect of CD532, mice harboring passaged N-Myc/myrAKT1 tumors derived from two individual patient samples were treated with either vehicle or CD532 60 mg/kg daily for two doses. To confirm the on-target effect of CD532, the tumors were harvested and assayed for N-Myc expression normalized to GAPDH expression. CD532-treated tumors exhibited a 31.3% mean reduction in N-Myc protein levels relative to vehicle-treated tumors (Figure 7G). Treatment of a larger cohort of mice bearing subcutaneous LASCPC-01 xenograft tumors with CD532 25 mg/kg twice per week significantly reduced tumor burden over vehicle treatment (Figure 7H).

**DISCUSSION**

Models of NEPC have been limited to human tumor xenografts with poorly defined genetic drivers and genetically engineered mouse models (i.e., TRAMP and prostate-specific conditional knockouts) that inactivate p53 and Rb (Berman-Booty and Knudsen, 2015). However, the protracted tumor latencies of these mouse models reflect the need for secondary oncogenic events to promote prostate tumorigenesis. In these systems, pinpointing the function of driver oncogenes that are activated during prostate cancer progression is challenging. We report that the deregulated expression of N-Myc and myrAKT1 in primary human prostate epithelial cells is sufficient to produce tumors with the characteristics of end-stage prostate cancer in the form of mixed NEPC and prostate adenocarcinoma. The abbreviated tumor latency and repeated observation of this phenotype in tumors derived from multiple unique human prostate samples indicate that N-Myc and activated AKT1 together are penetrant drivers of progression to NEPC.

Rapid castration-resistant proliferation and absence of AR expression are defining properties of the disease. N-Myc overexpression in the androgen-dependent LNCaP cell line has been shown to diminish AR expression levels (Beltran et al., 2011). The N-Myc/myrAKT1 tumors also showed low or absent...
AR expression and demonstrated primary androgen independence. These findings suggest that the acquisition of MYCN gene amplification and overexpression during prostate cancer evolution may allow escape from AR dependence and promote the emergence of CRPC and NEPC. Reciprocal regulation of c-Myc and AR expression has been described in prostate cancer (Gao et al., 2013; Ni et al., 2013), but the relationship between N-Myc and AR has not been explored.

Metastatic invasion of visceral organs is largely responsible for the exceedingly poor survival of patients with aggressive NEPC. N-Myc expression correlates with invasive and metastatic behavior in neuroblastoma, and the N-Myc transcriptional program in neuroblastoma appears to regulate multiple aspects of metastasis (Huang and Weiss, 2013). While primary N-Myc/myrAKT1 tumors in the subcutaneous compartment did not demonstrate invasion or metastasis, dissociated tumor cells introduced into the tail veins or prostates of mice readily colonized bone, lymph nodes, and visceral organs. Although the microenvironment likely accounts for the absence of distant spread from the subcutaneous xenograft tumors (Stephenson et al., 1992), secondary genetic events and clonal selection during culture may have also contributed to the metastatic phenotype.

The cellular origin of NEPC has not been clearly defined. The prevailing hypothesis is that prostate adenocarcinomas undergo transdifferentiation to NEPC, especially under the selective pressure of androgen deprivation (Beltran et al., 2014; Lin et al., 2014; Shen et al., 1997). This theory is supported by genetic analyses of human prostate tumors with concurrent neuroendocrine carcinoma and adenocarcinoma where common TP53 mutations and TMPRSS2-ERG rearrangements have been identified in both cancer types, suggesting a shared clonal origin (Hansel et al., 2009; Williamson et al., 2011). Our results functionally demonstrate that NEPC and prostate adenocarcinoma can both arise from a single N-Myc/myrAKT1 tumor cell clone derived from a prostate epithelial cell. Further, propagation of tumor cells in castrate conditions leads to enrichment of the NEPC over the prostate adenocarcinoma. These findings show directly an epithelial-to-neuroendocrine transition and prove that a common clone gives rise to these cancer subtypes in human prostate cancer, as has been proposed by prior studies (Beltran et al., 2014; Lin et al., 2014). Our data suggest that a subset of primary prostate adenocarcinoma with MYCN amplification and overexpression may acquire cancer stem cell properties that allow them to act as lurking clones capable of repopulating the tumor with NEPC after treatment. Consistent with this idea, previous work has shown that concurrent MYCN and AURKA amplification was identified in 65% of prostate adenocarcinomas from patients who later developed NEPC but in only 5% from an unselected population (Mosquera et al., 2013).

Our collective studies do not rule out the possibility that a benign neuroendocrine cell could also be a target of transformation giving rise to NEPC. In small-cell lung cancer, neuroendocrine cells and non-neuroendocrine epithelial cells have been found to be targets of transformation in a mouse model system, albeit with different efficiencies (Sutherland et al., 2011). Evaluation of this hypothesis in the human prostate with direct transformation studies is technically challenging due to the rarity of neuroendocrine cells in benign tissues and the lack of homogeneously expressed cell surface markers. In addition, we were unable to obtain outgrowths from human prostate luminal epithelial cells after introducing the oncogenes N-Myc and myrAKT1. This may reflect a limitation of our in vivo transformation assay as prior attempts to directly transform human luminal cells using this system have also been unsuccessful (Goldstein et al., 2010; Stoyanova et al., 2013). The advent of organoid cultures that enable the growth of luminal progenitor cells (Karthaush et al., 2014) may in the near future provide an opportunity to understand the functional impact of N-Myc overexpression and PI3K/AKT pathway activation in this population.

For decades, platinum-based chemotherapy has been the mainstay of treatment for aggressive human NEPC such as SCPC with dismal outcomes. In our studies, we functionally demonstrate that N-Myc drives NEPC and continuous expression of N-Myc is necessary for tumor maintenance. We propose that N-Myc is an attractive therapeutic target in this disease. Once considered impossible to target, the Myc family of oncoproteins can now be inhibited through a number of pharmacologic strategies (Dang, 2012). The positive feedback loop between N-Myc and Aurora A kinase identified in neuroblastoma (Otto et al., 2009) and NEPC (Beltran et al., 2011) provides one such opportunity. Our studies show that CD532 is highly active in our N-Myc/myrAKT1 tumor cells. CD532 potently inhibits Aurora A kinase activity and reduces N-Myc protein levels at sub-micromolar doses in vitro and substantially slows tumor growth in vivo. Based on these pre-clinical data, we believe that dual inhibition of N-Myc and Aurora A kinase warrants future clinical evaluation in patients with NEPC.

Lastly, the importance of N-Myc in the development of NEPC is highlighted by our prior contrasting finding that c-Myc combined with myrAKT1 in the same system generates adenosquamous carcinoma of the prostate but not NEPC (Stoyanova et al., 2013). The notion that Myc family members can drive distinct oncogenic differentiation pathways has been inferred from the amplification of specific Myc family members in several human cancers (Beltran, 2014). Compelling functional data in support of this idea has also come from a mouse model system in which the overexpression of MYC or MYCN combined with the loss of TP53 in mouse cerebellar neural progenitor cells produced distinct tumors akin to two different subgroups of human medulloblastoma (Kawauchi et al., 2012). The differential regulation of Myc transcriptional programs in human cancers and the mechanisms by which N-Myc initiates a neuroendocrine transformation program in prostate cancer warrant further study.

**EXPERIMENTAL PROCEDURES**

**Human Prostate Transformation Assay**

De-identified human prostate tissues were obtained from the UCLA Translational Pathology Core Laboratory and are exempt from UCLA Institutional Review Board approval. The processing of human prostate tissue, acquisition of epithelial subpopulations, lentiviral transduction, recombination with mouse UGSM, and subcutaneous grafting in NSG mice were performed as previously described (Goldstein et al., 2010). Subcutaneous implantation of transduced human prostate epithelial cell and UGSM grafts was performed in accordance with a protocol approved by the Animal Research Committee at UCLA. Mice were obtained from The Jackson Laboratory and mouse care and husbandry were performed according to the regulations of the Division of Laboratory Animal Medicine at UCLA.
Lentiviral Constructs
The cloning of lentiviral constructs is described in the Supplemental Experimental Procedures.

Cell Lines
Information on cell lines and culture conditions are provided in the Supplemental Experimental Procedures.

Histology, Immunohistochemistry, and Immunoblotting
Protocols and antibodies used for histology, immunohistochemistry, and immunoblotting of tissues and cell lines are described in the Supplemental Experimental Procedures.

Castration-Resistance and Metastasis Assays
Protocols for castration-resistance and metastasis assays are provided in the Supplemental Experimental Procedures.

Whole-Transcriptome Sequencing Analysis
Details regarding laser capture microdissection, RNA isolation, library preparation, RNA sequencing analysis, and generation of the NEPC gene signature are described in the Supplemental Experimental Procedures.

Copy Number Variation and Whole-Exome Sequencing Analysis
Protocols for copy number variation and whole-exome sequencing analysis are presented in the Supplemental Experimental Procedures.

Serial Dilution, Clonal Subline, and N-Myc Dependence Xenograft Studies
Protocols for serial dilution, clonal subline, and N-Myc dependence xenograft studies are described in the Supplemental Experimental Procedures.

Small Molecule Inhibitors
The sources of small molecule inhibitors and protocols for in vitro and in vivo CD532 studies are provided in the Supplemental Experimental Procedures.

ACCESSION NUMBERS
The RNA-seq and aCGH data reported in this article have been deposited in NCBI GEO: GSE77624 and GSE77368.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.ccel.2016.03.001.

AUTHOR CONTRIBUTIONS

ACKNOWLEDGMENTS
We thank Drs. Himisha Beltran and Mark Rubin at the Weill Medical College of Cornell University for sharing primary data from their human prostate cancer RNA-seq dataset. We thank the Translational Pathology Core Laboratory at UCLA, the California NanoSystems Institute Advanced Light Microscopy and Spectroscopy Shared Resource Facility, the UCLA Clinical Microarray Core, the High Throughput Sequencing Core at the Broad Stem Cell Research Center at UCLA, and the Clinical and Molecular Cytogenetics Laboratories at UCLA for core services. We thank the Harvard Medical School LINCS Center, which is funded by NIH grants (U54 HG006097, U54 HL127365), for use of publically available KINOMEscan data. This research was supported by the UCLA Hal Gaba Director’s Fund for Cancer Stem Cell Research. J.K.L. is supported by the Tower Cancer Research Foundation Career Development Award, a Prostate Cancer Foundation Young Investigator Award, and the UCLA Subspecialty Training and Advanced Research Program. J.W. Phillips is supported by the UCLA Tumor Cell Biology Training Grant (T32CA09056). B.A.S. is supported by the UCLA Tumor Immunology Training Grant (T32CA009120). J.W. Park is supported by a UCLA Broad Stem Cell Research Center Training Grant, and T.S. is supported by a Prostate Cancer Foundation Young Investigator Award and an NCI/NIH K99 Award (K99CA184397). W.C.G. is supported by a NIH K08 Award (K08NS079485) and the Alex’s Lemonade Stand Foundation. J.H. is supported by NIH grants (SR01CA172603-02, 2P50CA16642-39, 1R01CA181242-01A1, 1R01CA195505), the Department of Defense Prostate Cancer Research Program (W81XWH-12-1-0206), UCLA SPORE in Prostate Cancer, Prostate Cancer Foundation Honorable A. David Mazzone Special Challenge Award, and UCLA Jonsson Comprehensive Cancer Center Impact Grant. K.M.S and O.N.W. are Investigators of the Howard Hughes Medical Institute. O.N.W. is supported by an NIH grant (U01 CA164188-01A) and a Prostate Cancer Foundation Challenge Award. A.S., J.M.S., K.M.S., J.H., and O.N.W. are supported by a Stand Up To Cancer/Prostate Cancer Foundation/Prostate Dream Team Translational Cancer Research Grant (SU2C-AACR-DT0812). This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

Received: September 21, 2015
Revised: December 15, 2015
Accepted: March 1, 2016
Published: March 31, 2016

REFERENCES


